HYBRID EVENT: You can participate in person at Baltimore, Maryland, USA or Virtually from your home or work.

10th Edition of International Conference on Neurology and Brain Disorders

October 21-23, 2024

October 21 -23, 2024 | Baltimore, Maryland, USA
INBC 2017

K.L. Leenders

Speaker at Neurology Conferences - K.L. Leenders
University of Groningen, Netherlands
Title : FDG PET, DAT SPECT and olfaction in rapid eye movement sleep behavior disorder


Objective: Idiopathic rapid eye movement sleep behavior disorder (iRBD) is a well-known risk factor for Parkinson’s disease, and provides an opportunity to test biomarkers in the prodromal stage. Recently, expression of the Parkinson’s disease related metabolic pattern (PDRP) was used to predict conversion from iRBD to Parkinson’s disease. We compared PDRP expression in iRBD to striatal dopamine transporter (DAT) binding and olfaction.

Methods: PDRP expression z-scores were computed in 18F-FDG PET brain scans of 30 iRBD patients and 19 controls. PDRP z-scores were compared to z-scores in Parkinson’s disease (n=14) and dementia with Lewy bodies (n=14). Based on prior research, a cut-off z-score of 1.8 was used to indicate 100% specificity for Parkinson’s disease.

In 21/30 iRBD patients, DAT imaging with 123I-FP-CIT SPECT was performed. The relationship between pattern expression, DAT binding and olfactory function (Sniffin’ Sticks test) was studied.

Results: PDRP expression was higher in iRBD compared to controls (P=0.003), but lower compared to Parkinson’s disease. Seventeen iRBD patients (57%) had a z-score≥1.8. PDRP z-scores correlated to putamen DAT binding (r=-0.61, P=0.005). Loss of striatal DAT binding was observed in 9/21 patients (43%). Interestingly, of the 12 iRBD patients with a normally rated 123I-FP-CIT SPECT scan, 5 (42%) expressed the PDRP (z-score≥1.8). Olfactory dysfunction was observed in 23/26 iRBD subjects. There was no significant relationship between olfaction and PDRP z-scores or DAT binding.

Interpretation: The PDRP is a suitable biomarker for neurodegeneration in prodromal Parkinson’s disease, and its expression may be detected before the nigrostriatal pathway is affected.


Prof Dr K.L. Leenders is a clinical neurologist who trained at the University of Amsterdam.From 1982 until 1988 he worked at the Hammersmith Hospital London as Senior Registrar and in the PET research program at the MRC Cyclotron Unit. From 1989 until 1998 he was head of the movement disorder clinic of the Neurology Department at the Zurich University Hospital (Switzerland). At the same time he has been responsible for running a research program concerning movement disorders using PET radiotracer imaging techniques at the Paul Scherrer Institute, the national physics institute in Switzerland.